{"id":"comparator-infanrix","safety":{"commonSideEffects":[{"rate":"25–50%","effect":"Injection site pain, redness, or swelling"},{"rate":"10–25%","effect":"Fever"},{"rate":"10–20%","effect":"Fussiness or irritability"},{"rate":"5–15%","effect":"Drowsiness"},{"rate":"5–10%","effect":"Loss of appetite"}]},"_chembl":{"chemblId":"CHEMBL3983509","moleculeType":"Small molecule","molecularWeight":"434.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Infanrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses without causing disease. The vaccine primes both humoral (antibody) and cellular immunity to protect against these three bacterial infections. It is administered as part of the standard childhood immunization schedule.","oneSentence":"Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:30:42.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters)"}]},"trialDetails":[{"nctId":"NCT05116241","phase":"PHASE2","title":"Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children","status":"COMPLETED","sponsor":"ILiAD Biotechnologies","startDate":"2021-11-11","conditions":"Bordetella Pertussis, Whooping Cough","enrollment":368},{"nctId":"NCT04031846","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-04","conditions":"Pneumococcal Infections","enrollment":1184},{"nctId":"NCT03942406","phase":"PHASE2","title":"Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults","status":"COMPLETED","sponsor":"ILiAD Biotechnologies","startDate":"2019-06-15","conditions":"Pertussis, Whooping Cough","enrollment":300},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT00988884","phase":"PHASE3","title":"A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-10-21","conditions":"Human Papillomavirus Infection","enrollment":1241},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT00289913","phase":"PHASE4","title":"Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Hepatitis A Virus","enrollment":1274},{"nctId":"NCT01003431","phase":"PHASE3","title":"A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Rotavirus Gastroenteritis, Diphtheria, Tetanus","enrollment":""},{"nctId":"NCT00258154","phase":"PHASE3","title":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Rotavirus Disease","enrollment":403},{"nctId":"NCT00325130","phase":"PHASE3","title":"Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Neoplasms, Glandular and Epithelial, Diphtheria, Tetanus","enrollment":1042}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":60,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Comparator: Infanrix™","genericName":"Comparator: Infanrix™","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}